KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $74,363.25 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 7,627 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $9.75, for a total value of $74,363.25. Following the completion of the sale, the chief executive officer now directly owns 274,596 shares in the company, valued at approximately $2,677,311. This represents a 2.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

KalVista Pharmaceuticals Stock Down 4.8 %

KALV traded down $0.47 during trading on Monday, hitting $9.34. The company’s stock had a trading volume of 318,003 shares, compared to its average volume of 478,207. The firm’s 50 day moving average price is $10.90 and its two-hundred day moving average price is $11.82. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.39 and a 12 month high of $16.88. The stock has a market capitalization of $461.58 million, a price-to-earnings ratio of -2.66 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.04. On average, sell-side analysts forecast that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on KALV. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Thursday.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Vestal Point Capital LP raised its position in shares of KalVista Pharmaceuticals by 73.9% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after acquiring an additional 1,700,000 shares during the last quarter. Great Point Partners LLC bought a new stake in shares of KalVista Pharmaceuticals during the second quarter worth $15,768,000. Readystate Asset Management LP bought a new stake in KalVista Pharmaceuticals in the third quarter valued at about $2,084,000. Emerald Advisers LLC increased its holdings in KalVista Pharmaceuticals by 29.8% in the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after purchasing an additional 192,091 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after purchasing an additional 3,314 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).